Vaxcyte Toekomstige groei

Future criteriumcontroles 0/6

De winst van Vaxcyte zal naar verwachting dalen met 4.5% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 89.1% per jaar. De winst per aandeel zal naar verwachting afnemen met 2.2% per jaar.

Belangrijke informatie

-4.5%

Groei van de winst

-2.2%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	89.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	06 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:5VA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	21	-654	-516	-820	7
12/31/2025	N/A	-608	-544	-543	8
12/31/2024	N/A	-486	-509	-331	8
9/30/2024	N/A	-508	-616	-470	N/A
6/30/2024	N/A	-497	-582	-467	N/A
3/31/2024	N/A	-437	-483	-408	N/A
12/31/2023	N/A	-402	-365	-297	N/A
9/30/2023	N/A	-300	-245	-233	N/A
6/30/2023	N/A	-265	-220	-214	N/A
3/31/2023	N/A	-245	-199	-191	N/A
12/31/2022	N/A	-223	-176	-171	N/A
9/30/2022	N/A	-174	-163	-156	N/A
6/30/2022	N/A	-143	-153	-146	N/A
3/31/2022	N/A	-118	-144	-136	N/A
12/31/2021	N/A	-100	-128	-121	N/A
9/30/2021	N/A	-92	-87	-81	N/A
6/30/2021	N/A	-87	-70	-66	N/A
3/31/2021	N/A	-83	-48	-46	N/A
12/31/2020	N/A	-89	-48	-47	N/A
9/30/2020	N/A	-83	-52	-50	N/A
6/30/2020	N/A	-73	-48	-47	N/A
3/31/2020	N/A	-64	-53	-51	N/A
12/31/2019	N/A	-50	-48	-47	N/A
12/31/2018	N/A	-29	-32	-30	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 5VA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 5VA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 5VA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat 5VA volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat 5VA volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 5VA naar verwachting over 3 jaar hoog zal zijn

Vaxcyte Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Insufficient new directors

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

New major risk - Revenue and earnings growth

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

New major risk - Revenue and earnings growth

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

High number of new directors

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults

High number of new directors

Vaxcyte, Inc., Annual General Meeting, Jun 01, 2022

Vaxcyte, Inc. Announces Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in Adults

Vaxcyte, Inc. Announces the First Participants Dose in the Phase 1/2 Clinical Study of VAX-24

Vaxcyte, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

Less than half of directors are independent

Vaxcyte, Inc. Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven